Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Considering lifestyle and environment to maximize the economic value of R&D

Posted on November 10th, 2017 by in Pharma R&D

With an interest in systems approaches, I am always on the look-out for interesting papers in this area. A recent paper in Drug Discovery Today caught my eye for several reasons (1). The first was the extent of the problem with non-alcoholic liver disease. Continue reading “Considering lifestyle and environment to maximize the economic value of R&D” »

Why a reliable FAERS searching capability is essential for pharma companies

Posted on October 27th, 2017 by in Pharmacovigilance

In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »

Snakes (aka Chutes) and Ladders – failures and opportunities

Posted on October 13th, 2017 by in Pharma R&D

If there ever was a children’s game that would help prepare the next generation of pharmaceutical R&D scientists and researchers, it would be Snakes and Ladders (Chutes and Ladders in the US). Continue reading “Snakes (aka Chutes) and Ladders – failures and opportunities” »

Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis

Posted on July 5th, 2017 by in Pharma R&D

These days, there is a lot of focus on nutraceuticals and ‘natural products’, derived from nature or alternately synthesized as ‘nature-identical compounds’ and used in nutraceuticals products. Continue reading “Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis” »

  1. 1
  2. 2
  3. 3
  4. 4